DOCSLIB.ORG

For Effective Vaccination Policies in Europe PROTECTING HEALTH, SAVING LIVES EU Cooperation Against Vaccine-Preventable Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Effective Vaccination Policies in Europe PROTECTING HEALTH, SAVING LIVES EU Cooperation Against Vaccine-Preventable Diseases November 2019 - n°60 EUROPE & VACCINES For effective vaccination policies in Europe PROTECTING HEALTH, SAVING LIVES EU cooperation against vaccine-preventable diseases 2.7 million Worldwide MEASLES vaccines million 2 NEONATAL prevent TETANUS every year 1 million PERTUSSIS VACCINATION IN THE EU INFECTIOUS DISEASES ON THE RISE Influenza vaccination coverage rates V More than 14 000 measles & among people aged 65+ 696 rubella cases in 2017 UK 71% RO - 5 608 measles NL 67% IT - 5 098 measles EU 34% DE - 929 measles BG 2% GR - 967 measles EE 2% EU ACTION DISTRUST IN VACCINES Ensure ACCESS to vaccines for all 0% Control all vaccines to ensure HIGHEST SAFETY STANDARDS Share CLEAR, INDEPENDENT 45.5% and TRANSPARENT information “ I think vaccines More RESEARCH to develop new vaccines are not safe” Confidence Project Sources: ECDC; Eurostat; WHO; The Vaccine European Commission: ec.europa.eu/health/vaccination/overview_en European Centre for Disease Prevention and Control: ecdc.europa.eu @EU_Health #EUvaccines Health and Food Safety E UROP E & V ACCIN E S - F OR effe CTI ve V ACCINATION POLICI E S IN E UROP E | T HE E UROPEAN F ILES | 3 EDITORIAL EUROPE & VACCINES accination is the primary instrument interest of vaccination should be more clearly vaccination programmes. The Commission is for prevention in public health. Thanks highlighted. Providing reliable information considering the creation of a European virtual V to vaccination programmes, life to the general public and dispelling myths data warehouse on vaccine needs, which expectancy in the world is one of humanity’s about vaccines and vaccination through the could facilitate the voluntary exchange of greatest achievements. According to the exchange of good practices is key to ensure information on available supplies. This would WHO, vaccination can prevent between 2 and effective public health. ensure that the necessary measures are in 3 million deaths per year worldwide. place in the event of a pandemic. For several years now, the sub-optimal Nowadays, several European and neigh- vaccination coverage observed in Europe Vaccination policies fall within the purview bouring countries are facing the return of has led the European Commission to step of national authorities. However, the EU some epidemics thought to be long forgotten, up its vaccination efforts by working closely must ensure fair access to vaccines for all EU the resurgence of which is mainly due to a lack with Member States. In December 2018, citizens through free distribution in order to of vaccination coverage. the Council adopted a recommendation to remove major financial barriers, combat dis- strengthen EU cooperation against vaccine- information and build confidence in vaccines, In an increasingly digitalized and intro- preventable diseases. Subsequently, it estab- facilitating a vaccination pathway from an Vverted society, misinformation is on the rise, lished a roadmap to ensure better cooperation early age. social media pose a new challenge when it between Member States. A feasibility study on comes to maintaining confidence in immu- the development of a common EU vaccination Vaccination is first and foremost about nization. However, the use of digital tools map was launched this year. A draft common education for all of us. In this issue of The would facilitate and improve vaccination vaccination document, which could help EU European Files, we capture the responses of programmes throughout Europe, using citizens to continue their vaccination in the our institutions and hope to encourage a interoperability of systems, monitoring data, Member States, is expected to be completed public discussion faithful to the greater good. procurement and a real-time supply status, in 2022. preventing waste, all as a way of fighting fire Editor-in-Chief with fire. Europe plays an important role in the pro- LAURENT ULMANN duction of these vaccines. Several European Our policies and scientists must have a clear countries have experienced a shortage of and unambiguous narrative about the need vaccine production and supply which has for vaccination and its coverage. The collective hampered the implementation of their Management: The European Files / Les Dossiers Européens - 19 rue Lincoln, 1180 Brussels www.europeanfiles.eu - ISSN 1636-6085 - email: [email protected] Publication Director and Editor-in-Chief: Laurent ULMANN Layout & printing: VAN RUYS PRINTING Copyright: Shutterstock, European Commission 4 | T HE E UROPEAN F ILES | E UROP E & V ACCIN E S - F OR effe CTI ve V ACCINATION POLICI E S IN E UROP E Europe & Vaccines TABLE OF CONTENTS For effective vaccination policies in Europe The benefits of digital tools for improving Sustain vaccination programmes through a healthier immunisation programmes 6 vaccine ecosystem in an interconnected Europe 16 Krista Kiuru, Finnish Minister for Family Affairs and Social Corinne Bardone, Pharm D, Head of Global Vaccines Public Services Affairs, for Polio, Pertussis and Hib containing Vaccines, Sanofi Pasteur To eliminate measles in Germany: The Measles Protection Christina Klein, Manager, Global Vaccine Public Affairs, Act. Requirement for all children entering school or Sanofi Pasteur kindergarten to have both measles vaccinations 7 Jens Spahn, Germany’s Federal Health Minister Florence Baron-Papillon, Pharm D, Head of Public Affairs Europe for Vaccines, Sanofi Pasteur Place vaccination at the forefront of the public space 8 Agnès Buzyn, French Minister for Solidarity and Health, Looking ahead to the next decade for Extract from the article in European immunisation week immunization in Europe 19 Dr. Siddhartha Datta, Programme Manager, Vaccine- Dedicated supra-structural vaccination organizations: preventable Diseases and Immunization programme, WHO the driver of a successful vaccination schemes 10 Regional Office for Europe Maggie De Block, Belgian Minister of Social Affairs and Public Ms. Catharina de Kat, Communications, Web and Health and Asylum Policy and Migration Information Officer, Vaccine-preventable Diseases and Immunization programme, WHO Regional Office for Europe Promote vaccination, particularly the childhood immunisation programme and the HPV vaccine Securing a robust vaccine sector in Europe 20 for both girls and boys 11 Magdalena Rodriguez de Azero, Executive Director, Simon Harris, Irish Minister for Health Vaccines Europe European Commission roadmap on vaccination 12 Harnessing the power of partnerships to Anne Bucher, Director-General DG SANTE, European develop life-saving vaccines 22 Commission Dr. Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI) A cancer vaccine: how to eradicate virus-related cancers in Europe? 13 Vaccination, Population Health, and Véronique Trillet-Lenoir, Oncologist and MEP, Renew European Leadership 24 Europe, France, Member of the ENVI Committee David E. Bloom, Harvard T.H. Chan School of Public Health Boston, Massachusetts USA Clinical Evaluation of vaccines 14 Daniel Cadarette, Harvard T.H. Chan School of Public Health Director Executif of EMA Prof. Guido Rasi, Boston, Massachusetts USA Improving pan-european collaboration in tackling Raising awareness about the importance of vaccine-preventable diseases 15 vaccination in Europe for public health 25 ECDC Director Andrea Ammon, Monika Beňová, MEP (S&D Group), Member of the ENVI Committee E UROP E & V ACCIN E S - F OR effe CTI ve V ACCINATION POLICI E S IN E UROP E | T HE E UROPEAN F ILES | 5 Europe & Vaccines For effective vaccination policies in Europe Is Europe Prepared for the Future of Vaccines - The educational and preventive role 37 Vaccines Innovation? 26 Sara Cerdas, MEP (S&D Group), Member of the ENVI Dr. Emmanuel Hanon, Senior Vice President, Head of R&D, Committee GSK Vaccines Dr. Rino Rappuoli, Chief Scientist, GSK Vaccines The EU research programmes in support to vaccine Research & Innovation 38 Dr. Philippe Denoel, Head of External R&D, GSK Vaccines Irene Norstedt, Acting Director, People Directorate, Directorate-General for Research and Innovation, European Vaccination for patients with chronic conditions 28 Commission Marco Greco, President of European Patients’ Forum (EPF) Alessandra Martini, Policy officer, Directorate-General for Research and Innovation, European Commission Vaccine hesitancy: public health emergency 29 Rory Palmer, MEP (S&D Group), Member of the ENVI Julia Molto Lopez, Programme assistant EU policies, Committee Directorate-General for Research and Innovation, European Commission Resilient immunisation systems: looking Barbara Kerstiëns, Head of Unit Combatting diseases, beyond high vaccination rates 30 Directorate-General for Research and Innovation, European Sibilia Quilici, Public Policy Director, MSD Commission Raising awareness about the key role of health Vaccination in Europe – the crucial role of professionals - The role of physicians in vaccination 32 the health care provider 40 Prof. Dr Frank Ulrich Montgomery, President of the Pierre Van Damme, MD, PhD, vice-dean faculty of Medicine Standing Committee of European Doctors (CPME) and Health Sciences, director Centre for the Evaluation of Vaccination, University of Antwerp, Belgium. Vaccination in Pharmacies 33 Michał Byliniak, President of PGEU (The Pharmaceutical Maternal vaccination: A new and highly Group of the European Union) effective policy to improve European pertussis immunisation programmes 42 Independent control contributes to Benoit Soubeyrand Md, Blossom Vaccinology, Lyon, France ensuring vaccine quality 34 Susanne Keitel, Director of the EDQM,
Load more

Recommended publications
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Strategies for Increasing Uptake of Vaccination in Pregnancy in High
    Vaccine 36 (2018) 2751–2759 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Review Strategies for increasing uptake of vaccination in pregnancy in high-income countries: A systematic review ⇑ Kate Alexandra Bisset a,b, Pauline Paterson a, a The Vaccine Confidence Project, London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, United Kingdom b Imperial College Healthcare NHS Trust, South Wharf Road, St Mary’s Hospital, London W2 1NY, United Kingdom article info abstract Article history: Introduction: Vaccination in pregnancy is an effective method to protect against disease for the pregnant Received 29 November 2017 woman, foetus and new born infant. In England, it is recommended that pregnant women are vaccinated Received in revised form 22 March 2018 against pertussis and influenza. Improvement in the uptake of both pertussis and influenza vaccination Accepted 4 April 2018 among pregnant women is needed to prevent morbidity and mortality for both the pregnant women Available online 13 April 2018 and unborn child. Aim: To identify effective strategies in increasing the uptake of vaccination in pregnancy in high-income Keywords: countries and to make recommendations for England. Pertussis vaccine Methods: A systematic review of peer reviewed literature was conducted using a keyword search strategy Influenza vaccine Pregnancy applied across six databases (Medline, Embase, PsychInfo, PubMed, CINAHL and Web of Science). Articles Vaccine hesitancy were screened against an inclusion and exclusion criteria and papers included within the review were Maternal vaccination quality assessed. Strategies Results and conclusions: Twenty-two articles were included in the review. The majority of the papers included were conducted in the USA and looked at strategies to increase influenza vaccination in preg- nancy.
    [Show full text]
  • Advice on Priority Groups for COVID-19 Vaccination
    Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination 30 December 2020 Introduction This advice is provided to facilitate the development of policy on COVID- 19 vaccination in the UK. JCVI advises that the first priorities for the current COVID-19 vaccination programme should be the prevention of COVID-19 mortality and the protection of health and social care staff and systems. Secondary priorities could include vaccination of those at increased risk of hospitalisation and at increased risk of exposure, and to maintain resilience in essential public services. This document sets out a framework for refining future advice on a national COVID-19 vaccination strategy. This advice has been developed based on a review of UK epidemiological data on the impact of the COVID-19 pandemic so far (1), data on demographic and clinical risk factors for mortality and hospitalisation from COVID-19 (2-3), data on occupational exposure(4-7), a review on inequalities associated with COVID-19 (8), Phase I, II and III data on the Pfizer-BioNTech mRNA vaccine and the AstraZeneca vaccine, Phase I and II data on other developmental COVID-19 vaccines (9-20), and mathematical modelling on the potential impact of different vaccination programmes (21). Considerations Pfizer-BioNTech vaccine The Committee has reviewed published and unpublished Phase I/II/III safety and efficacy data for the Pfizer BioNTech mRNA vaccine. The vaccine appears to be safe and well-tolerated, and there were no clinically concerning safety observations. The data indicate high efficacy 1 in all age groups (16 years and over), including protection against severe disease and encouraging results in older adults.
    [Show full text]
  • XXV TAG Meeting
    XXV TAG Meeting Twenty-Fifth Meeting of the Technical Advisory Group (TAG) on Vaccine-preventable Diseases 9-11 July 2019 Cartagena, Colombia 1 TAG Members J. Peter Figueroa TAG Chair Professor of Public Health, Epidemiology & HIV/AIDS University of the West Indies Kingston, Jamaica Jon K. Andrus Adjunct Professor and Senior Investigator Center for Global Health, Division of Vaccines and Immunization University of Colorado Washington, DC, United States Pablo Bonvehi Scientific Director VACUNAR S.A. Buenos Aires, Argentina Roger Glass* Director Fogarty International Center & Associate Director for International Research NIH/JEFIC-National Institutes of Health Bethesda, MD, United States Akira Homma Chairman of Policy and Strategy Council Bio-Manguinhos Institute Rio de Janeiro, Brazil Arlene King Adjunct Professor Dalla Lana School of Public Health University of Toronto Ontario, Canada Nancy Messonnier* Director National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention Decatur, GA, United States José Ignacio Santos Secretary General Health Council Government of Mexico Mexico City, Mexico Cristiana M. Toscano 2 Head of the Department of Collective Health Institute of Tropical Pathology and Public Health, Federal University of Goiás Goiania, Brazil Cuauhtémoc Ruiz-Matus Ad hoc Secretary Unit Chief Comprehensive Family Immunization PAHO/WHO Washington, DC, United States * Not present at the meeting 3 Table of Contents Contents Acronyms ..........................................................................................................................................6
    [Show full text]
  • Protecting Young Children from Pertussis and Influenza
    San Francisco Department of Public Health Barbara A Garcia, MPA Edwin M Lee Director of Health Mayor Tomás J. Aragón, MD, DrPH Health Officer January 2014 Dear Perinatal and Pediatrics Providers in San Francisco: Re: Protecting Young Infants from Pertussis and Influenza Both the American Academy of Pediatrics (AAP) and the American College of Obstetrics and Gynecology (ACOG) concur with the CDC Advisory Committee on Immunization Practices (ACIP) recommendations for protecting young infants from pertussis and influenza. ACIP Recommendations to Prevent Pertussis ACIP Recommendations to Prevent Influenza Pregnant women should receive Tdap with every Women who are or will be pregnant during flu pregnancy, ideally between 27- 36 weeks gestation. season should receive Inactivated Influenza Vaccine (IIV). Postpartum women who do not receive a Tdap vaccine Postpartum women can receive either Live during pregnancy, and who have not previously received Attenuated Influenza Vaccine (LAIV) or IIV. Tdap, should get Tdap immediately postpartum. Household and Other Contacts: Adults and adolescents Household contacts: ACIP emphasizes influenza age > 11 years, who have not previously received Tdap, vaccinations for household contacts (including should get Tdap ideally >2 weeks before close contact with children) and caregivers of children aged ≤59 a newborn. This includes partners, fathers, siblings, months, with particular emphasis on vaccinating grandparents, caregivers, and healthcare professionals. contacts of children aged <6 months. General: Everyone
    [Show full text]
  • State of Nevada's COVID-19 Vaccination Program Playbook
    COVID-19 Vaccination Program Nevada’s Playbook for Statewide Operations V3 NEVADA STATE IMMUNIZATION PROGRAM; DIVISION OF PUBLIC & BEHAVIORAL HEALTH; DEPARTMENT OF HEALTH AND HUMAN SERVICES Table of Contents Executive Summary ....................................................................................................................................... 1 Acronyms ...................................................................................................................................................... 4 Section 1: Public Health Preparedness Planning .......................................................................................... 6 Improvement Planning ............................................................................................................................. 6 COVID-19 Vaccination Program Planning ................................................................................................. 6 Section 2: COVID-19 Organizational Structure and Partner Involvement .................................................... 9 Nevada Planning and Coordination Team (Internal) ................................................................................ 9 Roles and Responsibilities ................................................................................................................... 10 State-Local Coordination .................................................................................................................... 10 Tribal Communities ................................................................................................................................
    [Show full text]
  • Pertussis (Whooping Cough) by Getting the Tdap Vaccine
    Protect your Baby from the Start GET THE WHOOPING COUGH VACCINE IN YOUR 3RD TRIMESTER Tdap During Pregnancy PROVIDER RESOURCE TOOL KIT CONTENTS Letters of Support • CDC Dear Colleague Letter • ACOG Dear Colleague Letter Provider Backgrounders • MMWR: Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women — Advisory Committee on Immunization Practices (ACIP), 2012 • ACOG Committee Opinion, September 2017: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis Vaccination • ACOG Committee Opinion, April 2016: Integrating Immunizations into Practice • Standing Orders for Tdap Vaccination to Pregnant Women • Immunization Action Coalition: Pertussis Questions and Answers • CDC: Tdap Vaccine Information Statement (VIS) • CDC: Provide the best prenatal care to prevent pertussis • ACOG: Physician Script Concerning Tdap Vaccination • CDC: Making a Strong Vaccine Referral to Pregnant Women Patient Handouts • Society for Maternal-Fetal Medicine: Tdap Vaccination During Pregnancy • Minnesota Department of Public Health: Tdap Vaccine for Pregnant Women • Immunization Action Coalition: Cocooning Protects Babies • CDC: You Can Start Protecting your Baby from Whooping Cough Before Birth • ACOG: Frequently Asked Questions for Pregnant Women Concerning Tdap Vaccination • CDC: Poster Print Ad: Pregnant Woman • CDC: Poster Print Ad: Nursery • Survivor Story: The Van Tornhout Family • Get Them In On Time: Birth to 16 Years Immunization Schedule www.vaccinateindiana.org
    [Show full text]
  • Licensed and Recommended Inactivated Oral Choleravaccines: from Development to Innovative Deployment
    Tropical Medicine and Infectious Disease Review Licensed and Recommended Inactivated Oral CholeraVaccines: From Development to Innovative Deployment Jacqueline Deen 1 and John D. Clemens 2,3,* 1 Institute of Child Health and Human Development, National Institutes of Health, University of the Philippines, Pedro Gil Street, Ermita, Manila 1000, Philippines; [email protected] 2 International Centre for Diarrhoeal Disease Research, GPO Box 128, Dhaka 1000, Bangladesh 3 UCLA Fielding School of Public Health, 650 Charles E Young Drive South, Los Angeles, CA 90095-1772, USA * Correspondence: [email protected]; Tel.: +63-2-254-5205 Abstract: Cholera is a disease of poverty and occurs where there is a lack of access to clean water and adequate sanitation. Since improved water supply and sanitation infrastructure cannot be implemented immediately in many high-risk areas, vaccination against cholera is an important addi- tional tool for prevention and control. We describe the development of licensed and recommended inactivated oral cholera vaccines (OCVs), including the results of safety, efficacy and effectiveness studies and the creation of the global OCV stockpile. Over the years, the public health strategy for oral cholera vaccination has broadened—from purely pre-emptive use to reactive deployment to help control outbreaks. Limited supplies of OCV doses continues to be an important problem. We discuss various innovative dosing and delivery approaches that have been assessed and implemented and evidence of herd protection conferred by OCVs. We expect that the demand for OCVs will continue to increase in the coming years across many countries. Keywords: cholera; oral cholera vaccine; efficacy; effectiveness Citation: Deen, J.; Clemens, J.D.
    [Show full text]
  • Paving the Way for Immunization
    Paving the Way for Immunization XX Meeting of the Technical Advisory Group on Vaccine- preventable Diseases (TAG) 17-19 October 2012 Final Report 1 TECHNICAL ADVISORY GROUP ON VACCINE‐PREVENTABLE DISEASES XX MEETING: “PAVING THE WAY FOR IMMUNIZATION” Washington DC, 17‐19 October 2012 Members 2012 Dr. Ciro A. de Quadros Executive Vice President President Sabin Vaccine Institute Washington, D.C., United States Dr. Akira Homma Chairman Policy and Strategy Council, Bio ‐Manguinhos Institute Rio de Janeiro, Brazil Dr. Anne Schuchat Director National Center for Immunization and Respiratory Diseases (NCIRD) Centers for Disease Control and Prevention Atlanta, GA, United States Dr. Arlene King Chief Medical Officer Ministry of Health and Long‐term Care Ontario, Canada Dr. Jeanette Vega Managing Director Foundation Initiatives The Rockefeller Foundation New York, NY, United States Dr. José Ignacio Santos Preciado Professor Department of Experimental Medicine Head of Clinical Research Research Division School of Medicine, Universidad Nacional Autónoma de México (UNAM) Mexico City, Mexico _________________________________________________________________________________ 2 XX TAG Meeting, Washington DC, 2012 – Final Report Dr. Peter Figueroa (unable to attend) Chief Medical Officer Ministry of Health Kingston, Jamaica Dr. Ramiro Guerrero‐Carvajal (virtual participation) Director Research Center for Social Protection and Health Economy (PROESA) Cali, Colombia Roger Glass Director Fogarty International Center, NIH/JEFIC‐National Institutes of Health
    [Show full text]
  • IMMU-NEWS Immunizing Florida
    IMMU-NEWS Immunizing Florida. Protecting Health. Editorial Staff: Janet Compton, Cristina Dusek, Claudette Hummel, Deborah Kahn, Winter 2014 Jennifer Ouzts, Laura Rutledge, Valerie Shipley MESSAGE FROM THE SECTION ADMINISTRATOR CHARLES H. ALEXANDER Welcome to the Winter edition of IMMU-NEWS. Winter is finally here! Our infamous Florida winter weather gives us plenty of variety; some very chilly days and some warm days too. These shifts in weather can also lend to coughs, cold, and the flu. Don’t forget to get your flu shot this season—It’s not too late! Flu season is in full swing and what better way to protect your friends and family than with immunization. In this issue you will learn about pertussis, cervical cancer, HPV, and the importance of teen vaccinations. The Immunization Section has had several program staff changes of note since the last issue. Two CDC Public Health Advisors, Bobbie Strickland and Halima Dumas, have moved on to other positions within the CDC after two years of service with the Immunization Section. We wish them both much success in their new career ventures. We thank both ladies for their outstanding service. The Immunization Section welcomes In this Issue: four new staff members. Janet Compton • MESSAGE FROM THE SECTION ADMINISTRATOR joined the Clinical/Quality Improvement Unit as a Government Operations • Division of Disease Control and Health Protection Employee Consultant II. Robert Glenn joined the Recognition Program Field Operations team as an Operations • Perinatal Pertussis Prevention Strategies and Management Consultant II. Lastly, we welcome two new members to the • Standard Abbreviations in This Issue Florida SHOTS team; Ryan Richbourg • ACIP Recommended Immunization Schedules is a Tester and Larry McIntyre is a Training Consultant.
    [Show full text]
  • June 2006 ACIP Meeting Minutes
    DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL AND PREVENTION NATIONAL IMMUNIZATION PROGRAM Advisory Committee on Immunization Practices June 29-30, 2006 Atlanta, Georgia Record of the Proceedings This document has been archived for historical purposes. (7/1/2006) TABLE OF CONTENTS Page Attachment 1: List of Participants ...........................................................................................................A1.1 Attachment 2: Acronyms Used In This Report........................................................................................A2.1 Minutes of the Meeting.................................................................................................................................. 1 June 29, 2006 Opening Session .................................................................................................................................... 1 HUMAN PAPILLOMAVIRUS VACCINE................................................................................................. 2 Overview .......................................................................................................................................... 2 GARDASIL® Efficacy and Safety Data............................................................................................. 3 GARDASIL® Risk Management Plan............................................................................................... 7 GARDASIL® Post-Marketing Safety Surveillance...........................................................................
    [Show full text]
  • Immunization Newsletter
    Immunization Newsletter Volume XXXIV Number 5 Immunize and Protect Your Family October 2012 XX TAG Meeting Paving the Way for Immunization Bolivian Uru Chipaya Community Receives PAHO The XX Meeting of the Technical Advisory Group (TAG) on Vaccine- Immunization Award preventable Diseases of the Pan American Health Organization The Uru Chipaya Ethnic Group of the Oruro (PAHO) was held from 17-19 October 2012 in Washington, D.C. Department of Bolivia received the 2011 Pan The twentieth TAG Meeting addressed several topics including polio vaccines; use of thiom- American Health Organization (PAHO) Im- ersal in vaccines; age restriction on rotavirus vaccine administration; Decade of Vaccines; evi- munization Award for their activities to keep dence on pertussis; proposal for standardizing PAHO’s TAG procedures; PAHO’s Revolving immunization coverage close to 100% in Fund in the current global vaccine market; improving regional vaccine production capacity their area. The group was presented with a to meet the needs of the Americas; measles, rubella and Congenital Rubella Syndrome (CRS) certificate of recognition, as well as a mon- elimination in the Region of the Americas; Haiti’s immunization program; and cholera vaccina- etary gift in the amount of three thousand US tion in the Americas. dollars at the twentieth Meeting of PAHO’s Technical Advisory Group (TAG) on Vac- The slogan for the meeting, “Paving the Way for Immunization,” reflected the Region’s leader- cine-preventable Diseases. PAHO created the ship in immunization in the global context. The purpose of the meeting was to draft TAG recom- Immunization Award to recognize outstand- mendations on how to address current and future challenges facing immunization programs in ing contributions to a national immunization the Americas.
    [Show full text]